The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline
Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2023-10-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | https://actamedindones.org/index.php/ijim/article/view/2285 |
| _version_ | 1797355192008572928 |
|---|---|
| author | Muhamad Frendy Setyawan Ni Made Mertaniasih Soedarsono Soedarsono |
| author_facet | Muhamad Frendy Setyawan Ni Made Mertaniasih Soedarsono Soedarsono |
| author_sort | Muhamad Frendy Setyawan |
| collection | DOAJ |
| description | Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with the treatment outcomes of pulmonary MDR-TB patients at a tertiary referral hospital in East Java. Methods: This study was a retrospective, descriptive, and data analysis on 1053 pulmonary MDR-TB patients in tertiary referral hospital Dr Soetomo, East Java, Indonesia, with the SPSS software version 25 and Microsoft Excel 2021. Results: The study analyzed the MDR-TB treatment regimen following the latest guidelines from WHO (2020) at a tertiary referral hospital in East Java. This study shows that a bedaquiline-containing regimen started in January 2015 to July 2022 with the percentage of distribution (1, 3, 11, 4, 18, 13, 29, 21)% consecutively in the regimen. The treatment outcome profile of MDR-TB patients shows the average percentage of cured (15%), died (12%), lost-to-follow-up cases (27%), moved to an individualized regimen or a different health facility (42%), and currently in the evaluation stage (4%). Overall from January 2017 to July 2022, the number of LTFU cases decreased (42, 46, 29, 19, 8, 4)%. However, the cured case fluctuated between 2017-2022 (16, 28, 26, 32)% respectively after Bdq started to be included in the regimen regularly for treating RR/MDR-TB. Conclusion: After seven years of study, we revealed an association between adding bedaquiline to the regimen and the treatment success and decreasing lost-to-follow-up cases. |
| first_indexed | 2024-03-08T14:07:42Z |
| format | Article |
| id | doaj.art-1157ee51f9ae4f63b6a452b373608d67 |
| institution | Directory Open Access Journal |
| issn | 0125-9326 2338-2732 |
| language | English |
| last_indexed | 2024-03-08T14:07:42Z |
| publishDate | 2023-10-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj.art-1157ee51f9ae4f63b6a452b373608d672024-01-15T04:28:05ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322023-10-01554632The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on BedaquilineMuhamad Frendy Setyawan0Ni Made Mertaniasih1Soedarsono Soedarsono2Doctoral Program of Medical Science, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia1. Department of Medical Microbiology, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia. 2. Dr. Soetomo Hospital, Surabaya, Indonesia. 3. Tuberculosis Laboratory, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.1. Divison of Pulmonology, Department of Internal Medicine, Faculty of Medicine Hang Tuah University, Surabaya, Indonesia. 2. Dr. Soetomo Hospital, Surabaya, Indonesia. 3. Tuberculosis Laboratory, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with the treatment outcomes of pulmonary MDR-TB patients at a tertiary referral hospital in East Java. Methods: This study was a retrospective, descriptive, and data analysis on 1053 pulmonary MDR-TB patients in tertiary referral hospital Dr Soetomo, East Java, Indonesia, with the SPSS software version 25 and Microsoft Excel 2021. Results: The study analyzed the MDR-TB treatment regimen following the latest guidelines from WHO (2020) at a tertiary referral hospital in East Java. This study shows that a bedaquiline-containing regimen started in January 2015 to July 2022 with the percentage of distribution (1, 3, 11, 4, 18, 13, 29, 21)% consecutively in the regimen. The treatment outcome profile of MDR-TB patients shows the average percentage of cured (15%), died (12%), lost-to-follow-up cases (27%), moved to an individualized regimen or a different health facility (42%), and currently in the evaluation stage (4%). Overall from January 2017 to July 2022, the number of LTFU cases decreased (42, 46, 29, 19, 8, 4)%. However, the cured case fluctuated between 2017-2022 (16, 28, 26, 32)% respectively after Bdq started to be included in the regimen regularly for treating RR/MDR-TB. Conclusion: After seven years of study, we revealed an association between adding bedaquiline to the regimen and the treatment success and decreasing lost-to-follow-up cases.https://actamedindones.org/index.php/ijim/article/view/2285drug-resistant tuberculosistreatment regimenbedaquilinewho guidelinespulmonary tuberculosis |
| spellingShingle | Muhamad Frendy Setyawan Ni Made Mertaniasih Soedarsono Soedarsono The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline Acta Medica Indonesiana drug-resistant tuberculosis treatment regimen bedaquiline who guidelines pulmonary tuberculosis |
| title | The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline |
| title_full | The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline |
| title_fullStr | The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline |
| title_full_unstemmed | The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline |
| title_short | The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline |
| title_sort | profile of multidrug tuberculosis regimen and treatment outcomes in pulmonary mdr tb patients at the tertiary referral hospital dr soetomo east java indonesia a seven year retrospective study on bedaquiline |
| topic | drug-resistant tuberculosis treatment regimen bedaquiline who guidelines pulmonary tuberculosis |
| url | https://actamedindones.org/index.php/ijim/article/view/2285 |
| work_keys_str_mv | AT muhamadfrendysetyawan theprofileofmultidrugtuberculosisregimenandtreatmentoutcomesinpulmonarymdrtbpatientsatthetertiaryreferralhospitaldrsoetomoeastjavaindonesiaasevenyearretrospectivestudyonbedaquiline AT nimademertaniasih theprofileofmultidrugtuberculosisregimenandtreatmentoutcomesinpulmonarymdrtbpatientsatthetertiaryreferralhospitaldrsoetomoeastjavaindonesiaasevenyearretrospectivestudyonbedaquiline AT soedarsonosoedarsono theprofileofmultidrugtuberculosisregimenandtreatmentoutcomesinpulmonarymdrtbpatientsatthetertiaryreferralhospitaldrsoetomoeastjavaindonesiaasevenyearretrospectivestudyonbedaquiline AT muhamadfrendysetyawan profileofmultidrugtuberculosisregimenandtreatmentoutcomesinpulmonarymdrtbpatientsatthetertiaryreferralhospitaldrsoetomoeastjavaindonesiaasevenyearretrospectivestudyonbedaquiline AT nimademertaniasih profileofmultidrugtuberculosisregimenandtreatmentoutcomesinpulmonarymdrtbpatientsatthetertiaryreferralhospitaldrsoetomoeastjavaindonesiaasevenyearretrospectivestudyonbedaquiline AT soedarsonosoedarsono profileofmultidrugtuberculosisregimenandtreatmentoutcomesinpulmonarymdrtbpatientsatthetertiaryreferralhospitaldrsoetomoeastjavaindonesiaasevenyearretrospectivestudyonbedaquiline |